Median follow-up time for surviving patients was 54.9 months. The primary endpoint was postrecurrence overall survival (OS). The effect of tumor volume on clinical outcome was assessed by using 2 cutoff values of GTV, 20 and 80 cm(3). Results: Median postrecurrence survival time was 27.9 months, and the 2-, 3-, and 5-year estimated OS rates were 56.0%, 39.8% and 33.2%, respectively. The median GTV was 26.8 cm(3).

Patients with a GTV <20 cm(3) had significantly higher 2-year (69.0% vs. 28.6%) and 3-year (61.4% vs. 14.3%) OS rates than patients with a GTV >= 80 cm(3) (P = .004). Patients with isolated local or regional recurrence had significantly better OS than patients with combined local and regional recurrence ATM inhibitor (P = .001). Multivariate analysis showed that smaller GTV and isolated local or regional recurrence were independent favorable prognostic factors for OS. Conclusions: Postrecurrence OS of patients with postsurgical locoregionally recurrent NSCLC treated with definitive RT was excellent compared with previous findings. The GTV as a continuous variable

was a better predictor of OS than stage at recurrence and may be useful for stratifying the risk in patients with postsurgical recurrent NSCLC. (C) 2013 Elsevier Inc. All rights reserved.”
“Introduction: Between 60 and 80% of patients with B-cell acute lymphoblastic MDV3100 chemical structure leukemia show genetic abnormalities which influence the prognosis of the disease and the biology of the tumor.\n\nObjective: To analyze different genetic abnormalities in acute B lymphoblastic leukemia in children, its relationship with the immunophenotype and the proliferative rate compared with normal B cell precursors.\n\nMaterials and methods: We assessed immunophenotype,

DNA content and proliferative rate in 44 samples by flow cytometry, and translocations t(9; 22), t(12; 21), t(4; 11), and t(1; 19) by RT-PCR. Using a hierarchical cluster analysis, we identified some immunophenotypic patterns associated ICG-001 inhibitor to genetic abnormalities when compared with normal B cell precursors.\n\nResults: DNA quantification showed that 21% of the cases had high hyperdiploidy and 47.7% has low hyperdiploidy. The presence of hyperdiploidy was associated with increased tumor proliferation and aberrant immunophenotypes, including abnormal expression of CD10, TdT, CD38, and CD45 and an increased size of the lymphoblasts. The presence of t(9; 22) and t(12; 21) discriminates normal cells from tumor cells with aberrant immunophenotype in the expression of CD19, CD22, CD13, CD33, CD38, CD34, and CD45.\n\nConclusions: The aberrant immunophenotype profile detected in neoplastic cells along with abnormalities in the proliferative rate were significantly associated with DNA hyperdiploidy and clearly distinguished lymphoblasts with t(9; 22) and t(12; 21) from normal B cell precursors.